La chaîne d'options affiche les données clés des options sur actions de Rapport Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Rapport Therapeutics..

Rapport Therapeutics (NASDAQ:RAPP) Stock, Chaîne d'Options

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Mizuho analyst Maheep Mandloi maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Outperform and lowers the price target from $61 to $53.

News

Price Target

Analyst Ratings

ENPH

Mizuho Maintains Outperform on Enphase Energy, Lowers Price Target to $53

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>BMO Capital analyst Katja Jancic upgraded the rating for Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Market Perform to Outperform and raised the price target from $140 to $145. Nucor shares closed at $109.36 on Friday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Jordan Alliger upgraded Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Neutral to Buy and raised the price target from $387 to $410. Saia shares closed at $264.41 on Friday. <a href="https://www.benzinga.com/quote/SAIA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Nik Modi upgraded Church &amp; Dwight Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) from Sector Perform to Outperform and boosted the price target from $100 to $114. Church &amp; Dwight shares closed at $98.31 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Ronald Epstein upgraded The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raised the price target from $185 to $260. Boeing shares closed at $207.32 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Stephanie Moore upgraded the rating for Rollins, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) from Hold to Buy and raised the price target from $55 to $65. Rollins shares closed at $57.25 on Friday. <a href="https://www.benzinga.com/quote/rol/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NUE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-1024x575.png" alt="" class="wp-image-935167" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

SAIA

This Nucor Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Needham analyst Ami Fadia downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintains the price target from $130 to $130.

Downgrades

BPMC

Needham Downgrades Blueprint Medicines to Hold, Maintains Price Target to $130

Six in ten working-age Americans fear Social Security will vanish before they retire, a new DepositAccounts survey finds, underscoring a widening confidence gap as the program's main trust fund edges toward depletion in 2033.
What Happened: The poll of 1,047 non-retirees shows 59% doubt the program will exist by the time they hang up their paychecks. The anxiety is sharpest for Generation X, where 70% share the concern. That dread persists even though Social Security still supplies more than half of all income for 40% of today's retirees, according to the Social Security Administration.
As per this year's trustees report, the Old-Age and Survivors Insurance fund can pay full benefits for just eight more years. Once its reserves run dry, incoming payroll taxes would cover only 79% of promised checks. "It's not that far away. We're creeping up on it," certified-financial-planner Jaime Eckels <a href="https://www.cnbc.com/2025/05/30/majority-of-working-americans-fear-social-security-will-dry-up.html">told</a> CNBC, warning that the countdown has moved from abstract to immediate for many savers.
Polling elsewhere points in the same direction, or worse. Gallup in 2024 reports 80% of Americans now worry about Social Security's future, the highest share in two decades. Transamerica's 2024 middle-class survey shows 39% of households fear benefits "will be reduced or cease to exist."
See also: <a href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals">Moderna&#8217;s New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals</a>
Still, not every gauge is as bleak. The 2025 Retirement Confidence Survey from the Employee Benefit Research Institute found about half of workers remain at least "somewhat confident" the government will pay benefits of equal value to today's. Even so, 60% worry about cuts.
Why It Matters: Analysts stress that insolvency does not equal disappearance. "The truth is that it's highly, highly unlikely Social Security ‘won't be available,'" DepositAccounts quoted LendingTree's Matt Schulz as saying, urging savers to bolster private nest eggs rather than panic. That mirrors comments by BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) chief Larry Fink, who <a href="https://www.benzinga.com/personal-finance/25/03/44427073/larry-fink-says-the-u-s-needs-a-social-security-plan-where-every-american-can-grow-with-our-economy">recently told</a> an audience that the U.S. must modernize, not abandon, the program — citing the same <a href="https://www.benzinga.com/personal-finance/24/09/40817544/report-warns-of-16-500-annual-social-security-benefit-cut-for-dual-income-couples-by-2033">2033 deadline</a>.
Yet fear itself is already reshaping behavior. A growing number of claimants are <a href="https://www.benzinga.com/25/05/45265236/80000-more-americans-filed-for-social-security-in-march-compared-with-last-year-whats-driving-this-surge">taking benefits at 62</a> to grab what they can before any reforms bite, despite the <a href="https://www.benzinga.com/personal-finance/25/05/45354988/suze-orman-taking-your-social-security-payments-at-62-is-wrong-heres-why">permanent haircut</a> early filing brings.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/management/25/06/45719596/bill-gates-22-year-old-daughter-says-its-terrifying-for-the-boys-she-brings-home-to-meet-her-socially-awkward-dad-in-his-63-million-mansion">Bill Gates&#8217; 22-Year-Old Daughter Says It&#8217;s &#8216;Terrifying&#8217; For The Boys She Brings Home to Meet Her &#8216;Socially Awkward&#8217; Dad in His $63 Million Mansion</a>

Personal Finance

General

6 In 10 Americans Fear Social Security Will Vanish Before They Retire, As 2033 Insolvency Clock Ticks Louder

Mizuho analyst Maheep Mandloi maintains Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) with a Outperform and lowers the price target from $17 to $15.

CSIQ

Mizuho Maintains Outperform on Canadian Solar, Lowers Price Target to $15

MULN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

APDN

WIIM

MRNA

Moderna shares are trading higher after the company announced its new COVID-19 vaccine secured FDA clearance for seniors and at-risk individuals.

HC Wainwright &amp; Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $75 to $85.

VERA

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $85

Mizuho analyst John Roberts maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Outperform and lowers the price target from $100 to $82.

Mizuho Maintains Outperform on Westlake, Lowers Price Target to $82

Wells Fargo initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Equal-Weight rating and announces Price Target of $37.

Initiation

Wells Fargo Initiates Coverage On Aspen Insurance Hldgs with Equal-Weight Rating, Announces Price Target of $37

CRWV

CoreWeave shares are trading higher after announcing Applied Digital signed a 250MW AI data center lease with the company.

Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $280 to $295.

VEEV

Mizuho Maintains Outperform on Veeva Systems, Raises Price Target to $295

Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the pricing of its public offering of 28,595,553 shares of common stock (the "Common Stock") and 57,191,106 warrants (the "Warrants") to purchase Common Stock (including shares of Common Stock underlying warrants) at a public offering price of $0.2428. Each share of Common Stock is being sold together with two Warrants, with each Warrant to purchase one share of Common Stock. Each Warrant is exercisable immediately with an exercise price equal to 120% of the offering price ($0.2913 per share), and expires on the fifth anniversary of the issuance date, subject to certain adjustments.
The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting placement agent's fees and other offering expenses, are expected to be approximately $6.94 million. The Company intends to use the net proceeds of this offering for purchase of inventory and production costs of its vehicles and working capital.
American Trust Investment Services, Inc. is acting as exclusive placement agent in connection with the offering.

Offerings

FLYE

Fly-E Group Prices $6.94M Public Offering Of 28.6M Shares And 57.2M 5-Year Warrants At $0.2428 Per Unit

UBS analyst Damian Karas upgrades SPX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) from Neutral to Buy and raises the price target from $160 to $182.

SPXC

UBS Upgrades SPX Technologies to Buy, Raises Price Target to $182

PDSB

PDS Biotechnology shares are trading lower. The company provided updates and survival data for its VERSATILE-002 trial.

Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the "pre-funded warrants"), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series A warrants"), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series B warrants") and Series C warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series C warrants"). The combined public offering price of one pre-funded warrant, one Series A warrant, one Series B warrant and one Series C warrant, which are being sold together but are immediately separable, is $0.7499, which is equal to the combined offering price of the pre-funded warrants, Series A warrants, Series B warrants and Series C warrants, less the $0.0001 per share exercise price of the pre-funded warrants. The offering is expected to close on or about June 5, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Xilio.
The pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. The Series A warrants will be exercisable the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing sale price of our common stock is a minimum of $1.50 per share, with an exercise price of $0.75 per share of common stock, and will expire five years from the date of issuance. In addition, each Series A warrant will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to December 1, 2025; provided that this term will no longer apply to the Series A warrants beginning on the first the trading day immediately following a period of five consecutive trading days on which the closing sale price of our common stock is a minimum of $1.50 per share. The Series B Warrants will be exercisable on or after November 1, 2025, with an exercise price of $0.75 per share of common stock, and will expire on December 2, 2025, subject to certain extensions. The Series C Warrants will be exercisable on or after June 1, 2026, with an exercise price of $0.75 per share of common stock, and will expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B warrant held by a holder in proportion to the extent that the corresponding Series B warrant expires without being exercised, subject to certain extensions.
The initial gross proceeds from the offering are expected to be approximately $50.0 million before deducting underwriting discounts and commissions and offering expenses. The pre-funded warrants and Series A warrants may be exercised for cash or on a net exercise or "cashless" basis, and the Series B warrants and Series C warrants may be exercised for cash or on a net exercise or "cashless" basis provided there is no effective registration statement or prospectus available which covers the Series B warrants and Series C warrants and shares of common stock issuable upon exercise of the Series B warrants and Series C warrants. If all of the Series B warrants and Series C warrants are exercised in cash at their exercise price, the Company may receive additional gross proceeds from the offering of up to approximately $100.0 million before deducting underwriting discounts and commissions and offering expenses.

Xilio Therapeutics Prices $50M Public Offering Of Pre-Funded Warrants And Series A, B, C Warrants To Purchase 66.7M Shares Each At $0.7499 Per Unit; Co May Receive Additional Gross Proceeds From The Offering Of Up To ~$100M Before Deducting Underwriting Discounts And Commissions And Offering Expenses

U.S. Gold Corp. ("U.S. Gold," the "Company," "we," "our" or "us") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) is pleased to announce&nbsp;that we have met the criteria for inclusion in the broad-market Russell 3000 Index (the "Russell 3000") and the small-cap Russell 2000 Index (the "Russell 2000") at the conclusion of the Russell indexes annual reconstitution, effective after the U.S. market opens on&nbsp;June 30, 2025, according to a preliminary list of additions posted&nbsp;Friday, May 23, 2025.

USAU

U.S. Gold Corp Joins Russell 3000 And Russell 2000 Indexes Following Annual Reconstitution

Scotiabank analyst Maher Yaghi upgrades BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) from Sector Perform to Sector Outperform and announces C$39 price target.

TSX:BCE

Scotiabank Upgrades BCE to Sector Outperform, Announces C$39 Price Target

Morgan Stanley analyst Devin McDermott maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and raises the price target from $132 to $135.

Morgan Stanley Maintains Equal-Weight on EOG Resources, Raises Price Target to $135

Health Care

Press Releases

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Management

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Comments

Rapport Therapeutics

Rapport Therapeutics (RAPP) Options

Rapport Therapeutics (NASDAQ:RAPP) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL